Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients With Haemophilia A and Inhibitors

Study Evaluating Approach to Treatment of Haemophilia A and B in Spain

NCT00581438 ·Status: COMPLETED

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

NCT00221195 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385 ·Status: WITHDRAWN ·Phase: PHASE4

Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII

NCT00284193 ·Status: COMPLETED ·Phase: PHASE4

The FEIBA NovoSeven Comparative Study

NCT00166309 ·Status: COMPLETED ·Phase: NA

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX

NCT00710619 ·Status: COMPLETED

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

NCT02035384 ·Status: COMPLETED

Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®

NCT03006965 ·Status: COMPLETED

Epidemiology and Immunology of Hemophilia A Inhibitors

NCT00005518 ·Status: COMPLETED

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

NCT03588741 ·Status: TERMINATED ·Phase: PHASE3

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

NCT05662319 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

NCT02920398 ·Status: COMPLETED ·Phase: PHASE1

Personalized Prediction of Tolerance and Immunogenicity in Hemophilia

NCT01626105 ·Status: UNKNOWN

A Feasibility Study to Collect Data in Patients With Haemophilia

NCT00798499 ·Status: COMPLETED

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

NCT02020369 ·Status: COMPLETED ·Phase: PHASE3

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

NCT04563520 ·Status: RECRUITING ·Phase: PHASE3

Multidimensional Assessment of Chronic Pain in Severe Haemophilia A

NCT07096349 ·Status: RECRUITING

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

NCT01125813 ·Status: COMPLETED ·Phase: PHASE3

BAX 855 PK-guided Dosing

NCT02585960 ·Status: COMPLETED ·Phase: PHASE3

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

NCT01029340 ·Status: COMPLETED ·Phase: PHASE3

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

NCT00989196 ·Status: COMPLETED ·Phase: PHASE2

Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography

NCT03002480 ·Status: WITHDRAWN ·Phase: NA

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391 ·Status: COMPLETED ·Phase: PHASE4

TFPI Levels in Haemophilia A and B Patients

NCT04570696 ·Status: UNKNOWN

Study Evaluating ReFacto in Hemophilia A

NCT00038909 ·Status: COMPLETED ·Phase: NA